Your Privacy Matters

Parts of this website use cookies and content from third-party providers. More details can be read in our privacy policy, which also describes how you can amend your preferences at any time.

 Skip to main content

Insights

Big Pharma Inventory Benchmark Report 2026

Cover of the nVentic Big Pharma Inventory Trends Benchmarking Report 2026

Inside This Report:

  • See how combined inventories across 28 benchmarked pharma companies rose to $170bn in fiscal 2025.
  • Compare the split between large pharma, where median DIO rose 25 days, and the regular pharma group, where median DIO fell 24 days.
  • Understand the GLP-1 launch effect, acquisition impacts and planning dynamics behind the sharpest DIO movements.
Name
Optional
Data privacy
Read our Privacy Policy.

Share this insight:

All of our insights are available free and without registration. You can find more articles on our main Insights page.

More Insights

Other recent insights...
Content Subscription

Would you like to receive more content like this, direct to your inbox? We publish white papers on a range of supply chain topics approximately once every one to two months. Subscribe below and we will notify you of new content. Unsubscribe at any time.